These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17881272)

  • 1. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease.
    Hein LK; Meikle PJ; Hopwood JJ; Fuller M
    Mol Genet Metab; 2007 Dec; 92(4):336-45. PubMed ID: 17881272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease.
    Fuller M; Rozaklis T; Lovejoy M; Zarrinkalam K; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2008 Apr; 93(4):437-43. PubMed ID: 18162427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective reduction of bis(monoacylglycero)phosphate ameliorates the storage burden in a THP-1 macrophage model of Gaucher disease.
    Hein LK; Duplock S; Fuller M
    J Lipid Res; 2013 Jun; 54(6):1691-1697. PubMed ID: 23564732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid composition of microdomains is altered in a cell model of Gaucher disease.
    Hein LK; Duplock S; Hopwood JJ; Fuller M
    J Lipid Res; 2008 Aug; 49(8):1725-34. PubMed ID: 18427156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid composition of membrane rafts, isolated with and without detergent, from the spleen of a mouse model of Gaucher disease.
    Hattersley KJ; Hein LK; Fuller M
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):62-7. PubMed ID: 24220330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes.
    Trajkovic-Bodennec S; Bodennec J; Futerman AH
    Blood Cells Mol Dis; 2004; 33(1):77-82. PubMed ID: 15223015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic targets for Gaucher disease.
    Vitner EB; Vardi A; Cox TM; Futerman AH
    Expert Opin Ther Targets; 2015 Mar; 19(3):321-34. PubMed ID: 25416676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells.
    Newburg DS; Shea TB; Yatziv S; Raghavan SS; McCluer RH
    Exp Mol Pathol; 1988 Jun; 48(3):317-23. PubMed ID: 3371456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model.
    Balreira A; Lacerda L; Miranda CS; Arosa FA
    Br J Haematol; 2005 Jun; 129(5):667-76. PubMed ID: 15916690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coenzyme Q
    de la Mata M; Cotán D; Oropesa-Ávila M; Villanueva-Paz M; de Lavera I; Álvarez-Córdoba M; Luzón-Hidalgo R; Suárez-Rivero JM; Tiscornia G; Sánchez-Alcázar JA
    Orphanet J Rare Dis; 2017 Feb; 12(1):23. PubMed ID: 28166796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
    Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
    Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
    Prence EM; Chaturvedi P; Newburg DS
    J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.
    Reed MC; Schiffer C; Heales S; Mehta AB; Hughes DA
    Mol Genet Metab; 2018 Aug; 124(4):278-286. PubMed ID: 29934064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development.
    Wątek M; Piktel E; Wollny T; Durnaś B; Fiedoruk K; Lech-Marańda E; Bucki R
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipids: the nexus between Gaucher disease and insulin resistance.
    Fuller M
    Lipids Health Dis; 2010 Oct; 9():113. PubMed ID: 20937139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-Glucosidase inhibition in murine peritoneal macrophages by conduritol-B-epoxide: an in vitro model of the Gaucher cell.
    Newburg DS; Yatziv S; McCluer RH; Raghavan S
    Biochim Biophys Acta; 1986 Jun; 877(1):121-6. PubMed ID: 3087427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease.
    Mucci JM; Suqueli García F; de Francesco PN; Ceci R; Di Genaro S; Fossati CA; Delpino MV; Rozenfeld PA
    Gene; 2013 Dec; 532(2):186-91. PubMed ID: 24076352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress.
    Deganuto M; Pittis MG; Pines A; Dominissini S; Kelley MR; Garcia R; Quadrifoglio F; Bembi B; Tell G
    J Cell Physiol; 2007 Jul; 212(1):223-35. PubMed ID: 17443679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.
    Schueler UH; Kolter T; Kaneski CR; Zirzow GC; Sandhoff K; Brady RO
    J Inherit Metab Dis; 2004; 27(5):649-58. PubMed ID: 15669681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher disease: pathological mechanisms and modern management.
    Jmoudiak M; Futerman AH
    Br J Haematol; 2005 Apr; 129(2):178-88. PubMed ID: 15813845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.